MARKET

CYCN

CYCN

Cyclerion Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9600
+0.0100
+1.05%
Closed 19:25 08/10 EDT
OPEN
0.9754
PREV CLOSE
0.9500
HIGH
1.030
LOW
0.9301
VOLUME
239.47K
TURNOVER
--
52 WEEK HIGH
3.623
52 WEEK LOW
0.4613
MARKET CAP
41.71M
P/E (TTM)
-0.7612
1D
5D
1M
3M
1Y
5Y
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Cyclerion Therapeutics reports Q2 results
Cyclerion Therapeutics press release (<span class=...
Seekingalpha · 1d ago
BRIEF-Cyclerion Announces CY6463 Clinical Pipeline Progress, Q2 Results
BRIEF-Cyclerion Announces CY6463 Clinical Pipeline Progress, Q2 Results
Reuters · 1d ago
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 2d ago
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 07/28 14:37
BRIEF-Cyclerion Reports Positive Topline Clinical Data For CY6463
BRIEF-Cyclerion Reports Positive Topline Clinical Data For CY6463
Reuters · 07/28 11:31
Cyclerion Therapeutics Announces Topline Clinical Data For CY6463 In Patients With Cognitive Impairment Associated With Schizophrenia
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data from its clinical study of
Benzinga · 07/28 11:22
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well tolerated, with no reports of serious adverse events (SAEs)...
GlobeNewswire · 07/28 11:00
More
No Data
Learn about the latest financial forecast of CYCN. Analyze the recent business situations of Cyclerion Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CYCN stock price target is 9.00 with a high estimate of 14.00 and a low estimate of 4.000.
High14.00
Average9.00
Low4.000
Current 0.9600
EPS
Actual
Estimate
-0.29-0.22-0.14-0.07
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 115
Institutional Holdings: 23.45M
% Owned: 53.96%
Shares Outstanding: 43.45M
TypeInstitutionsShares
Increased
10
253.79K
New
3
143.95K
Decreased
17
827.19K
Sold Out
9
183.94K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Marsha Fanucci
Chief Executive Officer/Director
Peter Hecht
Chief Financial Officer/Secretary
Anjeza Gjino
Chief Operating Officer
Cheryl Gault
Chief Scientific Officer
Andreas Busch
Director
Steven Hyman
Independent Director
George Conrades
Independent Director
Errol De Souza
Independent Director
Ole Isacson
Independent Director
Stephanie Lovell
Independent Director
Terrance McGuire
Independent Director
Michael Mendelsohn
No Data
No Data
About CYCN
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.

Webull offers kinds of Cyclerion Therapeutics Inc stock information, including NASDAQ:CYCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCN stock methods without spending real money on the virtual paper trading platform.